UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 323

Sortiert nach

Endocrine-responsive breast cancer and strategies for combating resistance

Nature reviews. Cancer, 2002-02, Vol.2 (2), p.101-112

2002

Volltextzugriff (PDF)

Differential expression of estrogen receptor α, β1, and β2 in lobular and ductal breast cancer

Proceedings of the National Academy of Sciences - PNAS, 2014-02, Vol.111 (5), p.1933-1938

2014

Volltextzugriff (PDF)

A Randomized Trial of Exemestane after Two to Three Years of Tamoxifen Therapy in Postmenopausal Women with Primary Breast Cancer

The New England journal of medicine, 2004-12, Vol.351 (23), p.2461-2461

2004

Volltextzugriff (PDF)

A Pooled Analysis of Bone Marrow Micrometastasis in Breast Cancer

The New England journal of medicine, 2005-08, Vol.353 (8), p.793-802

2005

Volltextzugriff (PDF)

A Randomized Trial of Exemestane after Two to Three Years of Tamoxifen Therapy in Postmenopausal Women with Primary Breast Cancer

The New England journal of medicine, 2004-03, Vol.350 (11), p.1081-1092

2004

Volltextzugriff (PDF)

FoxO3a Transcriptional Regulation of Bim Controls Apoptosis in Paclitaxel-treated Breast Cancer Cell Lines

The Journal of biological chemistry, 2003-12, Vol.278 (50), p.49795-49805

2003

Volltextzugriff (PDF)

Quantification of cellular proliferation in tumor and normal tissues of patients with breast cancer by [18F]fluorothymidine -positron emission tomography imaging : Evaluation of analytical methods

Cancer research (Chicago, Ill.), 2005-11, Vol.65 (21), p.10104-10112

2005

Volltextzugriff (PDF)

Paclitaxel-induced nuclear translocation of FOXO3a in breast cancer cells is mediated by c-Jun NH2-terminal kinase and Akt

Cancer research (Chicago, Ill.), 2006-01, Vol.66 (1), p.212-220

2006

Volltextzugriff (PDF)

High-Dose Chemotherapy With Autologous Stem-Cell Support As Adjuvant Therapy in Breast Cancer: Overview of 15 Randomized Trials

Journal of clinical oncology, 2011-08, Vol.29 (24), p.3214-3223

2011

Volltextzugriff (PDF)

Ghrelin Increases Energy Intake in Cancer Patients with Impaired Appetite: Acute, Randomized, Placebo-Controlled Trial

The journal of clinical endocrinology and metabolism, 2004-06, Vol.89 (6), p.2832-2836

2004

Volltextzugriff (PDF)

Phase I Study of STX 64 (667 Coumate) in Breast Cancer Patients: The First Study of a Steroid Sulfatase Inhibitor

Clinical cancer research, 2006-03, Vol.12 (5), p.1585-1592

2006

Volltextzugriff (PDF)

Histone deacetylase inhibitors in cancer treatment

Anti-cancer drugs, 2002-01, Vol.13 (1), p.1-13

2002

Volltextzugriff (PDF)

Trichostatin A Is a Histone Deacetylase Inhibitor with Potent Antitumor Activity against Breast Cancer in Vivo

Clinical cancer research, 2001-04, Vol.7 (4), p.971-976

2001

Volltextzugriff (PDF)

Quality of Life in the Intergroup Exemestane Study: A Randomized Trial of Exemestane Versus Continued Tamoxifen After 2 to 3 Years of Tamoxifen in Postmenopausal Women With Primary Breast Cancer

Journal of clinical oncology, 2006-02, Vol.24 (6), p.910-917

2006

Volltextzugriff (PDF)

Estrogen receptor alpha in human breast cancer: occurrence and significance

Journal of mammary gland biology and neoplasia, 2000-07, Vol.5 (3), p.271-281

2000

Volltextzugriff (PDF)

FoxM1 is a downstream target and marker of HER2 overexpression in breast cancer

International journal of oncology, 2009-07, Vol.35 (1), p.57-68

2009

Volltextzugriff (PDF)

Voltage-Gated Sodium Channel Expression and Potentiation of Human Breast Cancer Metastasis

Clinical cancer research, 2005-08, Vol.11 (15), p.5381-5389

2005

Volltextzugriff (PDF)

Risk of Acute Myeloid Leukemia and Myelodysplastic Syndrome in Trials of Adjuvant Epirubicin for Early Breast Cancer: Correlation With Doses of Epirubicin and Cyclophosphamide

Journal of clinical oncology, 2005-06, Vol.23 (18), p.4179-4191

2005

Volltextzugriff (PDF)

Preoperative gefitinib versus gefitinib and anastrozole in postmenopausal patients with oestrogen-receptor positive and epidermal-growth-factor-receptor-positive primary breast cancer: a double-blind placebo-controlled phase II randomised trial

The lancet oncology, 2005-06, Vol.6 (6), p.383-391

2005

Volltextzugriff (PDF)

Abstract P1-09-04: Activity of CT7001 an orally bio-available cyclin-dependent kinase 7 selective inhibitor in models of triple negative breast cancer

Cancer research (Chicago, Ill.), 2018-02, Vol.78 (4_Supplement), p.P1-P1-09-04

2018

Volltextzugriff (PDF)

Abstract P1-10-05: ICEC0942, a new oral selective inhibitor of the cell cycle and transcriptional regulator CDK7 for the treatment of estrogen receptor positive and negative breast cancer

Cancer research (Chicago, Ill.), 2018-02, Vol.78 (4_Supplement), p.P1-P1-10-05

2018

Volltextzugriff (PDF)

ERβ1 Represses FOXM1 Expression through Targeting ERα to Control Cell Proliferation in Breast Cancer

The American journal of pathology, 2011-09, Vol.179 (3), p.1148-1156

2011

Volltextzugriff (PDF)

Expression of estrogen receptor β isoforms in normal breast epithelial cells and breast cancer: regulation by methylation

Oncogene, 2003-10, Vol.22 (48), p.7600-7606

2003

Volltextzugriff (PDF)

Phosphorylation of human estrogen receptor α at serine 118 by two distinct signal transduction pathways revealed by phosphorylation-specific antisera

Oncogene, 2002-07, Vol.21 (32), p.4921-4931

2002

Volltextzugriff (PDF)

Abstract P4-01-02: Early detection of residual breast cancer through a robust, scalable and personalized analysis of circulating tumour DNA (ctDNA) antedates overt metastatic recurrence

Cancer research (Chicago, Ill.), 2019-02, Vol.79 (4_Supplement), p.P4-P4-01-02

2019

Volltextzugriff (PDF)

1 – 25 von 323

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(306)
Mit Volltextzugriff
(287)

Publikationsform

Sprache

Englisch
(323)
Japanisch
(24)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Endocrine-responsive breast cancer and strategies for combating resistance

Differential expression of estrogen receptor α, β1, and β2 in lobular and ductal breast cancer

A Randomized Trial of Exemestane after Two to Three Years of Tamoxifen Therapy in Postmenopausal Women with Primary Breast Cancer

A Pooled Analysis of Bone Marrow Micrometastasis in Breast Cancer

A Randomized Trial of Exemestane after Two to Three Years of Tamoxifen Therapy in Postmenopausal Women with Primary Breast Cancer

FoxO3a Transcriptional Regulation of Bim Controls Apoptosis in Paclitaxel-treated Breast Cancer Cell Lines

Quantification of cellular proliferation in tumor and normal tissues of patients with breast cancer by [18F]fluorothymidine -positron emission tomography imaging : Evaluation of analytical methods

Paclitaxel-induced nuclear translocation of FOXO3a in breast cancer cells is mediated by c-Jun NH2-terminal kinase and Akt

High-Dose Chemotherapy With Autologous Stem-Cell Support As Adjuvant Therapy in Breast Cancer: Overview of 15 Randomized Trials

Ghrelin Increases Energy Intake in Cancer Patients with Impaired Appetite: Acute, Randomized, Placebo-Controlled Trial

Phase I Study of STX 64 (667 Coumate) in Breast Cancer Patients: The First Study of a Steroid Sulfatase Inhibitor

Histone deacetylase inhibitors in cancer treatment

Trichostatin A Is a Histone Deacetylase Inhibitor with Potent Antitumor Activity against Breast Cancer in Vivo

Quality of Life in the Intergroup Exemestane Study: A Randomized Trial of Exemestane Versus Continued Tamoxifen After 2 to 3 Years of Tamoxifen in Postmenopausal Women With Primary Breast Cancer

Estrogen receptor alpha in human breast cancer: occurrence and significance

FoxM1 is a downstream target and marker of HER2 overexpression in breast cancer

Voltage-Gated Sodium Channel Expression and Potentiation of Human Breast Cancer Metastasis

Risk of Acute Myeloid Leukemia and Myelodysplastic Syndrome in Trials of Adjuvant Epirubicin for Early Breast Cancer: Correlation With Doses of Epirubicin and Cyclophosphamide

Preoperative gefitinib versus gefitinib and anastrozole in postmenopausal patients with oestrogen-receptor positive and epidermal-growth-factor-receptor-positive primary breast cancer: a double-blind placebo-controlled phase II randomised trial

Abstract P1-09-04: Activity of CT7001 an orally bio-available cyclin-dependent kinase 7 selective inhibitor in models of triple negative breast cancer

Abstract P1-10-05: ICEC0942, a new oral selective inhibitor of the cell cycle and transcriptional regulator CDK7 for the treatment of estrogen receptor positive and negative breast cancer

ERβ1 Represses FOXM1 Expression through Targeting ERα to Control Cell Proliferation in Breast Cancer

Expression of estrogen receptor β isoforms in normal breast epithelial cells and breast cancer: regulation by methylation

Phosphorylation of human estrogen receptor α at serine 118 by two distinct signal transduction pathways revealed by phosphorylation-specific antisera

Abstract P4-01-02: Early detection of residual breast cancer through a robust, scalable and personalized analysis of circulating tumour DNA (ctDNA) antedates overt metastatic recurrence

Suchergebnisse filtern